# Intrathecal Rituximab in Progressive Multiple Sclerosis

> **NCT02545959** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier de PAU** · enrollment: 10 (actual)

## Conditions studied

- Multiple Sclerosis, Chronic Progressive
- Nervous System Diseases

## Interventions

- **DRUG:** Rituximab IT
- **DRUG:** methylprednisolone IV
- **DRUG:** Rituximab IV

## Key facts

- **NCT ID:** NCT02545959
- **Lead sponsor:** Centre Hospitalier de PAU
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-30
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-09-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545959, "Intrathecal Rituximab in Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02545959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*